Overview

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Status:
Completed
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).
Phase:
Phase 1
Details
Lead Sponsor:
Taris Biomedical LLC
Treatments:
Trospium chloride